共 489 条
[31]
Schober E(2018)HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study Diabetes Care 365 l1328-930
[32]
Svensson J(2018)Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study Diabetes Care 17 153-52
[33]
Almdal T(2015)Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes Diabetes Care 20 1755-836
[34]
Young R(2020)Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial Diabet Obes Metab 23 599-e1249
[35]
Warner JT(2019)Effects of sodium-glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta-analysis of randomized controlled trials Diabet Metab Res Rev 42 919-289
[36]
Delemer B(2019)Updated guidance for trusted systematic reviews: a new edition of the Cochrane for Interventions Cochrane Database Syst Rev 11 37-223
[37]
Souchon PF(2019)Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials BMJ 21 829-573
[38]
Holl RW(2018)Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus Cardiovasc Diabetol 105 e1235-39
[39]
Karges W(2018)Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes Diabet Obes Metab 107 280-1851
[40]
Kieninger DM(2018)Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials Diabet Obes Metab 302 R215-700